Published in Int J Clin Pharmacol Ther on May 01, 1999
Quercetin aglycone is bioavailable in murine pancreas and pancreatic xenografts. J Agric Food Chem (2010) 0.95
Magnetic core-shell nanoparticles for drug delivery by nebulization. J Nanobiotechnology (2013) 0.93
Quercetin, Inflammation and Immunity. Nutrients (2016) 0.92
Quercetin improves the in vitro development of porcine oocytes by decreasing reactive oxygen species levels. J Vet Sci (2013) 0.82
The phytoestrogen quercetin impairs steroidogenesis and angiogenesis in swine granulosa cells in vitro. J Biomed Biotechnol (2009) 0.82
Bimodal action of the flavonoid quercetin on basophil function: an investigation of the putative biochemical targets. Clin Mol Allergy (2010) 0.78
Modulatory effect of luteolin on redox homeostasis and inflammatory cytokines in a mouse model of liver cancer. Oncol Lett (2016) 0.75
Select dietary phytochemicals function as inhibitors of COX-1 but not COX-2. PLoS One (2013) 0.75
Establishment of a P-glycoprotein substrate screening model and its preliminary application. World J Gastroenterol (2004) 0.75
Oral administration of quercetin is unable to protect against isoproterenol cardiotoxicity. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.75
Reversal of haloperidol-induced orofacial dyskinesia by quercetin, a bioflavonoid. Psychopharmacology (Berl) (2003) 0.75
Bimodal interaction of coatomer with the p24 family of putative cargo receptors. Science (1996) 2.76
Grapefruit-drug interactions: can interactions with drugs be avoided? J Clin Pharmacol (2006) 1.82
Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol (2001) 1.57
AUIC--a general target for the optimization of dosing regimens of antibiotics? Ann Pharmacother (1996) 1.51
Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs. J Pharm Sci (1992) 1.45
Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology. Eur Respir J (2001) 1.43
Microdialysis in peripheral tissues. Adv Drug Deliv Rev (2000) 1.35
Microdialysis. A novel tool for clinical studies of anti-infective agents. Eur J Clin Pharmacol (2001) 1.34
Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clin Pharmacol Ther (1986) 1.32
Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J Immunol (2000) 1.26
Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther (1997) 1.25
Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol (1998) 1.17
Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokinet (1998) 1.17
Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol (1997) 1.16
Bioavailability and pharmacokinetics of natural volatile terpenes in animals and humans. Planta Med (2000) 1.15
Population pharmacokinetics of intramuscular quinine in children with severe malaria. Antimicrob Agents Chemother (2001) 1.04
Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung (1996) 1.04
Assessment of fusogenic properties of influenza virus hemagglutinin deacylated by site-directed mutagenesis and hydroxylamine treatment. Virology (1995) 1.03
Penetration of cefaclor into the interstitial space fluid of skeletal muscle and lung tissue in rats. Pharm Res (2001) 1.02
Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Pharm Res (1996) 0.99
A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans. J Antimicrob Chemother (2000) 0.99
Determination of free interstitial concentrations of piperacillin-tazobactam combinations by microdialysis. J Antimicrob Chemother (1998) 0.98
Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol (1996) 0.98
Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther (1999) 0.97
Comparison of plasma and free tissue levels of ceftriaxone in rats by microdialysis. J Pharm Sci (1997) 0.97
Adenovirus death protein, a transmembrane protein encoded in the E3 region, is palmitoylated at the cytoplasmic tail. Virology (1998) 0.96
Retarded processing of influenza virus hemagglutinin in insect cells. Virology (1991) 0.95
A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma. J Pharm Biomed Anal (2000) 0.95
Pharmacokinetics and pharmacodynamics of tilmicosin in sheep and cattle. J Vet Pharmacol Ther (1998) 0.94
Plant polyketide synthases: a chalcone synthase-type enzyme which performs a condensation reaction with methylmalonyl-CoA in the biosynthesis of C-methylated chalcones. Biochemistry (1998) 0.94
Bioavailability and pharmacokinetics of caffeoylquinic acids and flavonoids after oral administration of Artichoke leaf extracts in humans. Phytomedicine (2005) 0.94
Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Int J Clin Pharmacol Ther (1997) 0.93
Dependency of cortisol suppression on the administration time of inhaled corticosteroids. J Clin Pharmacol (1997) 0.93
A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids. J Pharmacokinet Biopharm (1999) 0.92
Determination of free extracellular concentrations of piperacillin by microdialysis. J Pharm Sci (1996) 0.92
An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy. AAPS PharmSci (2000) 0.92
Pharmacokinetics of triamcinolone acetonide and its phosphate ester. Eur J Clin Pharmacol (1985) 0.92
Simultaneous measurement of cortisol in serum and saliva after different forms of cortisol administration. Clin Chem (1992) 0.90
Identification of quercetin glucuronides in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl (2001) 0.90
Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. J Clin Pharmacol (2001) 0.89
Biowaiver monographs for immediate release solid oral dosage forms: prednisolone. J Pharm Sci (2007) 0.89
Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. Int J Clin Pharmacol Ther (2005) 0.88
Rapid chromatographic determination of cefotaxime and its metabolite in biological fluids. J Chromatogr (1985) 0.88
Kinetics of methylprednisolone and its hemisuccinate ester. Clin Pharmacol Ther (1985) 0.87
Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects. Ther Drug Monit (1986) 0.87
Comparison of antioxidative capacities and inhibitory effects on cholesterol biosynthesis of quercetin and potential metabolites. Phytomedicine (2002) 0.86
Pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral administration. J Clin Pharmacol (1997) 0.86
Desensitization of brain opiate receptor mechanisms by gonadal steroid treatments that stimulate luteinizing hormone secretion. Endocrinology (1988) 0.85
Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans. Br J Clin Pharmacol (1999) 0.85
Pharmacokinetics of dexamethasone and its phosphate ester. Biopharm Drug Dispos (1987) 0.85
HPLC determination of dexamethasone in human plasma and its application to an in vitro release study from endovascular stents. Pharmazie (2006) 0.84
Pharmacokinetics of dichloroacetate in adult patients with lactic acidosis. J Clin Pharmacol (1997) 0.84
Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form. Infection (2005) 0.84
Simultaneous assay of propranolol, diltiazem and metabolites of diltiazem in human plasma by liquid chromatography. J Pharm Biomed Anal (1990) 0.84
Pharmacokinetic properties of beta-lactamase inhibitors. Int J Clin Pharmacol Ther (1999) 0.84
Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharm Res (1995) 0.84
Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients. J Clin Pharm Ther (2011) 0.83
Relationship between serum and free interstitial concentrations of cefodizime and cefpirome in muscle and subcutaneous adipose tissue of healthy volunteers measured by microdialysis. J Clin Pharmacol (1997) 0.83
Local treatment of respiratory infections with antibiotics. Drug Intell Clin Pharm (1987) 0.83
A pharmacokinetic/pharmacodynamic approach to predict total prednisolone concentrations in human plasma. J Pharmacokinet Pharmacodyn (2007) 0.83
Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol (1992) 0.82
Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs. Pharm Res (2000) 0.82
Differential fatty acid selection during biosynthetic S-acylation of a transmembrane protein (HEF) and other proteins in insect cells (Sf9) and in mammalian cells (CV1). J Biol Chem (1996) 0.82
Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients. J Clin Pharmacol (1991) 0.82
Evaluation of a brain-targeting zidovudine chemical delivery system in dogs. Antimicrob Agents Chemother (1997) 0.82
A review of the effects of chronic exercise and physical fitness level on resting pharmacokinetics. Int J Clin Pharmacol Ther (2003) 0.81
Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. J Clin Pharmacol (1997) 0.81
Serum cytokine levels in neonates with congenital diaphragmatic hernia. Klin Padiatr (2011) 0.81
Changes in cortical evoked potentials as correlates of the efficacy of weak analgesics. Pain (1982) 0.81
Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol (1995) 0.81
Pharmacokinetics and pharmacodynamics of dexamethasone sodium-m-sulfobenzoate (DS) after intravenous and intramuscular administration: a comparison with dexamethasone phosphate (DP). J Clin Pharmacol (2001) 0.81
Soft cannabinoid analogues as potential anti-glaucoma agents. Pharmazie (2002) 0.81
Post-translational folding of the influenza C virus glycoprotein HEF: defective processing in cells expressing the cloned gene. J Gen Virol (1994) 0.81
Urinary metabolites of flavonoids and hydroxycinnamic acids in humans after application of a crude extract from Equisetum arvense. Phytomedicine (1999) 0.80
Pharmacokinetic/pharmacodynamic modeling of cortisol suppression after oral administration of fluocortolone. J Clin Pharmacol (1996) 0.80
Effect of fat distribution on the pharmacokinetics of cortisol in obesity. Int J Clin Pharmacol Ther (1998) 0.80
Influence of the Duffy antigen on pharmacokinetics and pharmacodynamics of recombinant monocyte chemoattractant protein (MCP-1, CCL-2) in vivo. Int J Immunopathol Pharmacol (2009) 0.80
Improved delivery through biological membranes. XXXL: Solubilization and stabilization of an estradiol chemical delivery system by modified beta-cyclodextrins. J Pharm Sci (1988) 0.79
Non-compartmental analysis of pharmacokinetic data after multiple intravenous and oral administration. Pharmazie (1997) 0.79
[Quantification of the attenuation of pain sensation through evoked potentials after the application of mild analgesics (author's transl)]. EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb (1980) 0.79
Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers. J Clin Pharmacol (2000) 0.79
A selective HPLC/RIA for the determination of budesonide. J Pharm Biomed Anal (1998) 0.79
Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions. J Pharm Sci (1997) 0.79
Evoked potentials as objective parameters for the analgesic response of weak analgesics. Adv Neurol (1982) 0.79
Pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm Res (1996) 0.79
High-performance liquid chromatographic assay of a central nervous system (CNS)-directed estradiol chemical delivery system and its application after intravenous administration to rats. Pharm Res (1988) 0.79
[Pharmacokinetics and pharmacodynamics of prednisolone following extremely high dosage as prednisolone hemisuccinate]. Arzneimittelforschung (1987) 0.79
Pharmacokinetics and pharmacodynamics of enantiomers of ibuprofen and flurbiprofen after oral administration. Int J Clin Pharmacol Ther (1997) 0.78
Pharmacokinetic/pharmacodynamic evaluation of the NHE inhibitor eniporide. J Clin Pharmacol (2001) 0.78
Increased erythrocyte and protein binding of codeine in patients with sickle cell disease. J Pharm Sci (1993) 0.78
Plasma and dermal pharmacokinetics of terpinen-4-ol in rats following intravenous administration. Pharmazie (2013) 0.78
Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters. Results from the TALIP study. Int J Clin Pharmacol Ther (2003) 0.78
Pharmacokinetic modelling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages. J Clin Pharm Ther (2014) 0.78
Pitfalls in pharmacokinetic multicompartment analysis. J Pharmacokinet Biopharm (1998) 0.78
Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids. Int J Clin Pharmacol Ther (1999) 0.77
Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep. Pharm Res (1994) 0.77
Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations. Int J Antimicrob Agents (2004) 0.77
Pharmacokinetic interaction between endogenous cortisol and exogenous corticosteroids. Pharmazie (1995) 0.77